PLK4 inhibitor enters clinical trial

Very excited about this news. The first PLK4 inhibitor is entering Phase 1 clinical trial. We showed that chemical inhibition of PLK4 is synthetic lethal with chromosomal amplification of TRIM37 across cancers. We focused our studies on neuroblastoma and breast cancer. Based on our findings, Repare Therapeutics announced their plans to initiate monotherapy trials to treat high-risk neuroblastoma patients with an oral PLK4 inhibitor (>80% TRIM37 amplification).  

Check out our paper in Nature: TRIM37 controls cancer-specific vulnerability to PLK4 inhibition